It has been applied in phase I clinical trials in patients with myelodysplastic syndromes and refractory acute myeloid leukemia (AML).38 Similarly, αβ T cells engineered to secrete antibodies were used for a diverse set of therapeutic strategies.39 For instance, previous studies reported that targeted delivery of a PD-1-blocking single-chain antibody fragment (scFv) by CAR-T cells enhanced antitumor efficacy in vivo.40 These cells may optimize clinical applications and generate novel concepts for adoptive immunotherapy in the future.41 The gene discussed is PDCD1; the disease is myelodysplastic syndrome.